Gelesis Holdings Gross Profit 2021-2022 | GLS

Gelesis Holdings gross profit from 2021 to 2022. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
Gelesis Holdings Annual Gross Profit
(Millions of US $)
2021 $
2020 $
2019 $
Gelesis Holdings Quarterly Gross Profit
(Millions of US $)
2022-03-31 $3
2021-12-31
2021-09-30
2021-06-30
2021-03-31 $0
2020-12-31
2020-09-30
2020-06-30
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.122B $0.011B
Gelesis is a consumer-centered biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Gelesis, formerly known as Capstar Special Purpose Acquisition Corp., is based in BOSTON.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $165.407B 10.06
Bio-Rad Laboratories (BIO.B) United States $14.121B 30.63
QIAGEN (QGEN) Netherlands $10.180B 16.07
Biohaven Pharmaceutical Holding (BHVN) United States $10.170B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.223B 0.00
Arcus Biosciences (RCUS) United States $1.792B 45.42
Emergent Biosolutions (EBS) United States $1.625B 6.95
Myovant Sciences (MYOV) United Kingdom $1.313B 0.00
Zymeworks (ZYME) Canada $0.365B 0.00
Ambrx Biopharma (AMAM) United States $0.110B 0.00
Enzo Biochem (ENZ) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.099B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00